Choose Your Location
|
![]() |
RICHMOND, Va. (Map) -
To participate in the live conference call, please dial 866-202-1971 (U.S. callers) or 617-213-8842 (international), and provide passcode 85261742. A live webcast of the call will also be available at http://phx.corporate-ir.net/playerlink.zhtml?c=122332&s=wm&e=1907655. Please allow extra time prior to the webcast to register, download and install any necessary audio software.
The webcast will be archived for 30 days, and a telephone replay of the
call will be available for seven days, beginning at
About Insmed
Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements which are made pursuant
to provisions of Section 21E of the Securities Exchange Act of 1934. Investors
are cautioned that such statements in this release, including statements
relating to planned clinical study design, regulatory and business strategies,
strategic alternatives, plans and objectives of management and growth
opportunities for existing or proposed products, constitute forward-looking
statements which involve risks and uncertainties that could cause actual
results to differ materially from those anticipated by the forward-looking
statements. The risks and uncertainties include, without limitation, risks
that strategic alternatives may never be consummated, product candidates may
fail in the clinic or may not be successfully marketed or manufactured, we may
lack financial resources to complete development of product candidates, the
FDA may interpret the results of studies differently than us, competing
products may be more successful, demand for new pharmaceutical products may
decrease, the biopharmaceutical industry may experience negative market
trends, our entrance into the follow-on biologics market may be unsuccessful,
our common stock could be delisted from The NASDAQ Capital Market and other
risks and challenges detailed in the Company's filings with the U.S.
Securities and Exchange Commission, including the Company's Annual Report on
Form 10-K for the year ended
Investor Relations Contact: Brian Ritchie - FD 212-850-5683 brian.ritchie@fd.com Corporate Communications Contact: John Procter - Gibraltar Associates 202-879-5808 jprocter@gibraltar-llc.com
|
|


